{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:09:06Z","timestamp":1793088546879,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,9,8]],"date-time":"2011-09-08T00:00:00Z","timestamp":1315440000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00198-011-1742-7","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T12:48:34Z","timestamp":1315399714000},"page":"1141-1150","source":"Crossref","is-referenced-by-count":50,"title":["Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta"],"prefix":"10.1007","volume":"23","author":[{"given":"R.","family":"Bargman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Posham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Boskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"DiCarlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Raggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pleshko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,8]]},"reference":[{"key":"1742_CR1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"1742_CR2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S (2005) Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 20:758\u2013763","journal-title":"J Bone Miner Res"},{"key":"1742_CR3","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1359\/JBMR.050312","volume":"20","author":"D Gatti","year":"2005","unstructured":"Gatti D, Viapiana O, Lippolis I, Braga V, Prizzi R, Rossini M, Adami S (2005) Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 20:1323\u20131326","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"1742_CR4","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","volume":"119","author":"FH Glorieux","year":"2007","unstructured":"Glorieux FH (2007) Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics 119(Suppl 2):S163\u2013S165","journal-title":"Pediatrics"},{"key":"1742_CR5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","volume":"20","author":"AD Letocha","year":"2005","unstructured":"Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977\u2013986","journal-title":"J Bone Miner Res"},{"key":"1742_CR6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.rhu.0000208490.22492.09","volume":"12","author":"E Madenci","year":"2006","unstructured":"Madenci E, Yilmaz K, Yilmaz M, Coskun Y (2006) Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 12:53\u201356","journal-title":"J Clin Rheumatol"},{"key":"1742_CR7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","volume":"363","author":"R Sakkers","year":"2004","unstructured":"Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427\u20131431, see comment","journal-title":"Lancet"},{"key":"1742_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/08035250500434785","volume":"95","author":"A Vallo","year":"2006","unstructured":"Vallo A, Rodriguez-Leyva F, Rodriguez Soriano J (2006) Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 95:332\u2013339","journal-title":"Acta Paediatr"},{"key":"1742_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11154-008-9074-4","volume":"9","author":"MS Cheung","year":"2008","unstructured":"Cheung MS, Glorieux FH (2008) Osteogenesis Imperfecta: update on presentation and management. Rev Endocr Metab Disord 9:153\u2013160","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"1742_CR10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metabol 96(2):355","journal-title":"J Clin Endocrinol Metabol"},{"key":"1742_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","volume":"170","author":"SL Teitelbaum","year":"2007","unstructured":"Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427\u2013435","journal-title":"Am J Pathol"},{"key":"1742_CR12","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149\u20132157","journal-title":"J Clin Endocrinol Metab"},{"key":"1742_CR13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"1742_CR14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJNH Kostenuik","year":"2009","unstructured":"Kostenuik PJNH, McCabe J, Warmington K, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (human\/murine) RANKL. J Bone Miner Res 24:182\u2013195","journal-title":"J Bone Miner Res"},{"key":"1742_CR15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","volume":"68","author":"AP Armstrong","year":"2008","unstructured":"Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68:92\u2013104","journal-title":"Prostate"},{"key":"1742_CR16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119\u2013129","journal-title":"Clin Exp Metastasis"},{"key":"1742_CR17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1359\/jbmr.2002.17.2.192","volume":"17","author":"LM Childs","year":"2002","unstructured":"Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM (2002) In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17:192\u2013199","journal-title":"J Bone Miner Res"},{"key":"1742_CR18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jor.20469","volume":"26","author":"D Delos","year":"2008","unstructured":"Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MP, Camacho NP (2008) The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta. J Orthop Res 26:153\u2013164","journal-title":"J Orthop Res"},{"key":"1742_CR19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1902\/jop.2007.070073","volume":"78","author":"Q Jin","year":"2007","unstructured":"Jin Q, Cirelli JA, Park CH, Sugai JV, Taba M Jr, Kostenuik PJ, Giannobile WV (2007) RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 78:1300\u20131308","journal-title":"J Periodontol"},{"key":"1742_CR20","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1359\/jbmr.060905","volume":"21","author":"HK Kim","year":"2006","unstructured":"Kim HK, Morgan-Bagley S, Kostenuik P (2006) RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res 21:1946\u20131954","journal-title":"J Bone Miner Res"},{"key":"1742_CR21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.179.1.266","volume":"179","author":"RE Miller","year":"2007","unstructured":"Miller RE, Branstetter D, Armstrong A, Kennedy B, Jones J, Cowan L, Bussiere J, Dougall WC (2007) Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 179:266\u2013274","journal-title":"J Immunol"},{"key":"1742_CR22","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00198-007-0363-7","volume":"18","author":"MS Ominsky","year":"2007","unstructured":"Ominsky MS, Kostenuik PJ, Cranmer P, Smith SY, Atkinson JE (2007) The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys. Osteoporos Int 18:1073\u20131082","journal-title":"Osteoporos Int"},{"key":"1742_CR23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1359\/jbmr.080109","volume":"23","author":"MS Ominsky","year":"2008","unstructured":"Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina M, Geng Z, Grisanti M, Tan HL, Corbin T, McCabe J, Simonet WS, Ke HZ, Kostenuik PJ (2008) RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 23:672\u2013682","journal-title":"J Bone Miner Res"},{"key":"1742_CR24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00223-005-0161-1","volume":"78","author":"J Padagas","year":"2006","unstructured":"Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D (2006) The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 78:35\u201344","journal-title":"Calcif Tissue Int"},{"key":"1742_CR25","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","volume":"35","author":"N Saidenberg-Kermanac'h","year":"2004","unstructured":"Saidenberg-Kermanac'h N, Corrado A, Lemeiter D, deVernejoul MC, Boissier MC, Cohen-Solal ME (2004) TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200\u20131207","journal-title":"Bone"},{"key":"1742_CR26","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1359\/JBMR.050601","volume":"20","author":"M Stolina","year":"2005","unstructured":"Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ (2005) RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 20:1756\u20131765","journal-title":"J Bone Miner Res"},{"key":"1742_CR27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","volume":"50","author":"J Zwerina","year":"2004","unstructured":"Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G (2004) Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 50:277\u2013290","journal-title":"Arthritis Rheum"},{"key":"1742_CR28","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","volume":"90","author":"SD Chipman","year":"1993","unstructured":"Chipman SD, Sweet HO, McBride DJ Jr, Davisson MT, Marks SC Jr, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR (1993) Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A 90:1701\u20131705","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1742_CR29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1359\/JBMR.050108","volume":"20","author":"D King","year":"2005","unstructured":"King D, Jarjoura D, McEwen HA, Askew MJ (2005) Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta. J Bone Miner Res 20:987\u2013993","journal-title":"J Bone Miner Res"},{"key":"1742_CR30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","volume":"69","author":"NP Camacho","year":"2001","unstructured":"Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL (2001) A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int 69:94\u2013101","journal-title":"Calcif Tissue Int"},{"key":"1742_CR31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S8756-3282(02)00974-2","volume":"32","author":"KD Evans","year":"2003","unstructured":"Evans KD, Lau ST, Oberbauer AM, Martin RB (2003) Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta. Bone 32:268\u2013274","journal-title":"Bone"},{"key":"1742_CR32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","volume":"52","author":"EA McCarthy","year":"2002","unstructured":"McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP (2002) Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model. Pediatr Res 52:660\u2013670","journal-title":"Pediatr Res"},{"key":"1742_CR33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008200903108472","volume":"51","author":"R Bargman","year":"2010","unstructured":"Bargman R, Huang A, Boskey A, Raggio C, Pleshko N (2010) RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res 51:123\u2013131","journal-title":"Connect Tissue Res"},{"key":"1742_CR34","unstructured":"Bargman R, Boskey A, DiCarlo E, Posham R, Raggio C, Verdelis K, Pleshko N (2009) Osteopetrosis-like changes after treatment with high and low dose OPG-Fc in the diaphyseal regions of infant mice. The Endocrine Society's 91st Annual Meeting Abstract. pp. P2\u2013196"},{"key":"1742_CR35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","volume":"36","author":"BM Misof","year":"2005","unstructured":"Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP (2005) Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone 36:150\u2013158","journal-title":"Bone"},{"key":"1742_CR36","unstructured":"Bouxsein Ml Fau - Boyd SK, Boyd Sk Fau - Christiansen BA, Christiansen Ba Fau - Guldberg RE, Guldberg Re Fau - Jepsen KJ, Jepsen Kj Fau - Muller R, Muller R Guidelines for assessment of bone microstructure in rodents using micro-computed tomography"},{"key":"1742_CR37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/002215540405200312","volume":"52","author":"L Filgueira","year":"2004","unstructured":"Filgueira L (2004) Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols. J Histochem Cytochem 52:411\u2013414","journal-title":"J Histochem Cytochem"},{"key":"1742_CR38","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1359\/jbmr.090215","volume":"24","author":"MS Ominsky","year":"2009","unstructured":"Ominsky MS, Stolina M, Li X, Corbin TJ, Asuncion FJ, Barrero M, Niu QT, Dwyer D, Adamu S, Warmington KS, Grisanti M, Tan HL, Ke HZ, Simonet WS, Kostenuik PJ (2009) One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 24:1234\u20131246","journal-title":"J Bone Miner Res"},{"key":"1742_CR39","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1359\/jbmr.071207","volume":"23","author":"JA Gasser","year":"2008","unstructured":"Gasser JA, Ingold P, Venturiere A, Shen V, Green JR (2008) Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 23:544\u2013551","journal-title":"J Bone Miner Res"},{"key":"1742_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6\u201316","journal-title":"J Bone Miner Res"},{"key":"1742_CR41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000093967","volume":"182","author":"S Blouin","year":"2006","unstructured":"Blouin S, Moreau MF, Basle MF, Chappard D (2006) Relations between radiograph texture analysis and microcomputed tomography in two rat models of bone metastases. Cells Tissues Organs 182:182\u2013192","journal-title":"Cells Tissues Organs"},{"key":"1742_CR42","unstructured":"Kimmel Db Fau - Jee WS, Jee WS A quantitative histologic analysis of the growing long bone metaphysis"},{"key":"1742_CR43","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1210\/er.2003-0038","volume":"26","author":"JD Veldhuis","year":"2005","unstructured":"Veldhuis JD, Roemmich JN, Richmond EJ, Rogol AD, Lovejoy JC, Sheffield-Moore M, Mauras N, Bowers CY (2005) Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 26:114\u2013146","journal-title":"Endocr Rev"},{"key":"1742_CR44","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","volume":"91","author":"F Rauch","year":"2006","unstructured":"Rauch F, Munns C, Land C, Glorieux FH (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268\u20131274","journal-title":"J Clin Endocrinol Metab"},{"key":"1742_CR45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14310\/horm.2002.1226","volume":"8","author":"PD Papapetrou","year":"2009","unstructured":"Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96\u2013110","journal-title":"Hormones (Athens)"},{"issue":"3","key":"1742_CR46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B Jonsson","year":"2010","unstructured":"Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2010) Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1742-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-011-1742-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-011-1742-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:08:40Z","timestamp":1558609720000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1742-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,8]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1742-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,8]]}}}